CONGENITAL BLEEDING DISORDER
Clinical trials for CONGENITAL BLEEDING DISORDER explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL BLEEDING DISORDER trials appear
Sign up with your email to follow new studies for CONGENITAL BLEEDING DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for young boys with rare bleeding disorder
Disease control CompletedThis trial tested a new, long-acting version of a missing clotting protein (Factor IX) in young boys with severe hemophilia B who had little to no prior treatment. The goal was to see if regular injections could safely prevent bleeding episodes and effectively treat bleeds when t…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for kids with severe bleeding disorder
Disease control CompletedThis study tested a medication called N8-GP in young children with severe hemophilia A who had never received treatment. The goal was to see if it was safe and effective at preventing bleeding episodes and stopping bleeds when they occurred. Researchers followed 124 boys under ag…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for kids with rare bleeding disorder
Disease control CompletedThis trial tested a new, long-acting medication (N9-GP) to control bleeding in children with severe hemophilia B. It involved 25 boys under 13 who had previously used other treatments. The main goals were to see if the drug was safe, how well it prevented and treated bleeds, and …
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC